Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C

This study has been completed.
Information provided by (Responsible Party):
Digna Biotech S.L. Identifier:
First received: May 10, 2010
Last updated: February 4, 2013
Last verified: February 2013
The general aim of this study is to determine if 3 MIU of IFN-α5 in monotherapy, and 1,5 MIU of IFN-α5 combined with 1,5 MIU of IFN- α2b, are safe dose levels as well as to investigate the antiviral efficacy and pharmacodynamics (PD) of such doses and drugs in treatment-experienced HCV patients with genotype 1 chronic infection, after 29 days of treatment. It is also intended to determine pharmacokinetics (PK) of the safe dose achieved of IFN-α5 in monotherapy.

Condition Intervention Phase
Chronic Hepatitis C Virus Infection
Genotype 1
Treatment-Experienced Patients
Drug: Interferon α-5
Drug: Interferon-α5 plus Interferon-α 2b
Drug: Interferon α-2b (INTRON® A)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II, Multicenter, Randomized, Open,Active-Controlled, ClinicalTrial to Evaluate PK, PD, Safety and Tolerability Of Interferon Alfa 5, S.C. 3 Times Per Week, For 29 Days, To Treat-Experienced Pat. With Genotype-1 Chronic Hepatitis C

Resource links provided by NLM:

Further study details as provided by Digna Biotech S.L.:

Primary Outcome Measures:
  • Safe dose level [ Time Frame: 29 days of treatment ]


    • To determine if 3 MIU of IFN-α5 are well tolerated and if not, to find a safe dose level for IFN-α5.
    • To determine if 1.5 MIU of IFN-α5 in combination with 1.5 MIU of IFN-α2b (IFN-α5 + IFN-α2b) are well tolerated and if not, to find a safe dose level for the combination of IFN-α5 and IFN-α2b.


    • To analyze IFN-α5 preliminary antiviral efficacy at the dose of 3 MIU, or the safe dose level identified in Phase I.
    • Primary safety endpoints: Occurrence of AE (classified into mild, moderate and severe)

Secondary Outcome Measures:
  • pharmacodynamic and pharmacokinetic parameters [ Time Frame: 29 days of treatment ]


    • To obtain pharmacokinetic parameters of IFN-α5 in monotherapy after single and multiple dose administration
    • To obtain pharmacodynamic parameters of IFN-α5 in monotherapy and in combination with IFN-α2b


    • To analyze IFN-α5 + IFN-α2b preliminary antiviral efficacy and comparison between IFN-α5 in monotherapy, IFN-α5 + IFN-α2b and IFN-α2b in monotherapy.
    • To obtain pharmacodynamic parameters after treatment with IFN-α5, IFN-α5 + IFN-α2b or IFN-α2b.

Enrollment: 70
Study Start Date: May 2010
Study Completion Date: January 2013
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Interferon α-5 Drug: Interferon α-5
3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
Experimental: Interferon α-5 plus Interferon α-2b Drug: Interferon-α5 plus Interferon-α 2b
Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
Active Comparator: Interferon α-2b (INTRON® A) Drug: Interferon α-2b (INTRON® A)
3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients aged ≥18 years old,
  2. With chronic hepatitis C (CHC) infection diagnosed by seropositivity for anti-HCV antibodies or detectable HCV-RNA, at least 6 months prior to screening.
  3. Patients with CHC infection of genotype 1 (1a, 1b or mixed 1a/1b)
  4. Defined as relapsers: those CHC patients who had achieved virologic response (HCV-RNA non detectable) at any time during the standard care of treatment for CHC with IFN-α2 or PegIFN-α2 + ribavirin, and maintained it trough the end of treatment at week 48 weeks, but HCV-RNA detection occurs before 6 months post-treatment.
  5. In whom liver cirrhosis has been ruled out through fibro-scan or liver biopsy within 24 months prior to study enrolment.
  6. With a serum HCV viral load ≥ 100.000 IU/mL at screening
  7. With alanine-aminotransferase (ALT) and aspartate-aminotransferase (AST) serum measurements at screening less than 5 times of their upper limits of normal (ULN)
  8. With a body mass index (BMI) of at least 18 kg/m2, but not exceeding 36 kg/m2.
  9. For female subjects with childbearing potential: use of a known highly effective method of birth control
  10. For male subjects with partners of child bearing potential: use of appropriate contraceptive methods.
  11. Is able to effectively communicate with the investigator and other testing center personnel.
  12. Is able to participate and willing to give written informed consent and comply with the study restrictions.

Exclusion Criteria(principal):

  1. Hepatitis C infection of genotype 2, 3 or 4 or any mixed genotype (1/2, 1/3 and 1/4).
  2. A positive ELISA for HIV-1 or HIV-2.
  3. Hepatitis B virus (HBV) infection based on the presence of HBsAg.
  4. Hepatitis A virus (HAV) infection based on the presence of antiHAV-IgM. (AM 4)Criteria deleted
  5. Decompensated liver disease, or history of decompensated liver disease.
  6. History or other evidence of a medical condition associated with decompensated renal, immunologically mediated, chronic pulmonary, cardiac, thyroid, severe retinopathy, severe psychiatric, organ transplantation, cancer, seizure disorder or pancreatitis diseases.
  7. An active or suspected malignancy or history of malignancy within the last five years.
  8. Patients with a documented drug and alcohol addiction free history of at least 12 months who are, in the opinion of the investigator unlikely to relapse, may be enrolled in the study.
  9. Positive results for drug abuse at screening.Occasional use of cannabis previously to randomization is not an exclusion criteria -under investigator team criteria-. The patient should be advised of abstinence during the trial (AM 6)
  10. Haemoglobin <12.0g/dL for women, and <13.0g/dL for men at screening.
  11. White blood cell count <2000 cells/mm3 at screening.
  12. Absolute neutrophil count <1500 cells/mm3 at screening.
  13. Platelet count <100.000 cells/mm3 at screening.
  14. ALT and AST levels ≥ 5 xULN at screening.
  15. Prothrombin time INR prolonged to 1.5xULN at screening.
  16. TSH an T4 outside normal limits and not adequately controlled thyroid function at screening.
  17. Poorly controlled diabetes mellitus as evidenced by HbA1c >7.5% at screening.
  18. Alfa-fetoprotein value >100ng/mL at screening.
  19. Total bilirubin >1.5xULN with ratio of direct/indirect >1, at screening unless predominantly conjugated and reflecting Gilbert's disease
  20. Estimated creatinine clearance of 30 mL/minute or less at screening.
  21. Women who are confirmed to be pregnant
  22. People with known hypersensitivity to any ingredient of the investigational agents
  23. Patients who are at risk of bleeding.
  24. Haemoglobinopathy
  25. Screening ECG QTc value ≥ 450ms and/or clinically significant ECG findings.
  26. History of clinically significant drug allergies.
  27. Participation in a clinical study with an investigational drug, biologic, or device within 3 months prior to anticipated dose administration.
  28. Any chronic viral (including HSV), bacterial, mycobacterial, fungal, parasitic, or protozoal infection.
  29. Requirement for chronic systemic corticosteroids.
  30. Receiving systemic antivirals, hematopoietic growth factor, or immunomodulatory treatment within 30 days prior to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01121731

Centre 013
A Coruña, Spain
Centre 004
Barcelona, Spain
Centre 005
Barcelona, Spain
Centre 008
Barcelona, Spain
Centre 011
Barcelona, Spain
Centre 014
Granada, Spain
Centre 015
León, Spain
Centre 002
Madrid, Spain
Centre 003
Madrid, Spain
Centre 006
Madrid, Spain
Centre 009
Madrid, Spain
Centre 016
Madrid, Spain
Centre 001
Pamplona, Spain
Centre 012
Santander, Spain
Centre 010
Sevilla, Spain
Sponsors and Collaborators
Digna Biotech S.L.
Principal Investigator: Jesús Prieto, MD, PhD Clínica Universidad de Navarra. Spain
  More Information

Responsible Party: Digna Biotech S.L. Identifier: NCT01121731     History of Changes
Other Study ID Numbers: NAHE001-CHC-01
2009-012924-10 ( EudraCT Number )
Study First Received: May 10, 2010
Last Updated: February 4, 2013

Keywords provided by Digna Biotech S.L.:
Chronic Hepatitis C Viral Infection
Interferon alfa-5

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Virus Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on April 28, 2017